Coherus BioSciences, Inc. (CHRS): Price and Financial Metrics

Coherus BioSciences, Inc. (CHRS): $15.07

0.31 (+2.10%)

POWR Rating

Component Grades













Add CHRS to Watchlist
Sign Up

Industry: Biotech


of 486

in industry


  • CHRS scores best on the Value dimension, with a Value rank ahead of 97.19% of US stocks.
  • The strongest trend for CHRS is in Momentum, which has been heading down over the past 31 weeks.
  • CHRS's current lowest rank is in the Sentiment metric (where it is better than 1.58% of US stocks).

CHRS Stock Summary

  • Coherus BioSciences Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than 86.78% of US listed stocks.
  • With a year-over-year growth in debt of 117.86%, Coherus BioSciences Inc's debt growth rate surpasses 91.65% of about US stocks.
  • Coherus BioSciences Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -20.06%, greater than the shareholder yield of just 12.67% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Coherus BioSciences Inc, a group of peers worth examining would be FBIO, INFN, MBII, PTCT, and DTIL.
  • Visit CHRS's SEC page to see the company's official filings. To visit the company's web site, go to

CHRS Price Target

For more insight on analysts targets of CHRS, see our CHRS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $25.25 Average Broker Recommendation 1.5 (Moderate Buy)

CHRS Stock Price Chart Interactive Chart >

Price chart for CHRS

CHRS Price/Volume Stats

Current price $15.07 52-week high $22.22
Prev. close $14.76 52-week low $12.90
Day low $14.66 Volume 866,900
Day high $15.07 Avg. volume 1,141,514
50-day MA $14.11 Dividend yield N/A
200-day MA $16.58 Market Cap 1.14B

Coherus BioSciences, Inc. (CHRS) Company Bio

Coherus Biosciences is a pure-play biosimilar platform company that develops and commercializes high-quality therapeutics for major regulated markets. The company was founded in 2010 and is based in Redwood City, California.

CHRS Latest News Stream

Event/Time News Detail
Loading, please wait...

CHRS Latest Social Stream

Loading social stream, please wait...

View Full CHRS Social Stream

Latest CHRS News From Around the Web

Below are the latest news stories about Coherus BioSciences Inc that investors may wish to consider to help them evaluate CHRS as an investment opportunity.

Coherus: Does The Market Need Another Anti-PD1?

Peter Wilcox/iStock via Getty ImagesIn the last 12 months, I have covered Coherus BioSciences (CHRS) twice, and despite my liking for the company, it has continued to trade sideways and downwards. The stock saw a major spike and then a fall on Jan. 27 (ish) and then again another one...

Avisol Capital Partners on Seeking Alpha | June 18, 2021

Polyarticular Juvenile Idiopathic Arthritis Drug Market Detailed Analysis and Growth Strategies By Biocon Ltd,Coherus BioSciences Inc,Livzon Pharmaceutical Group Inc

This report studies the Polyarticular Juvenile Idiopathic Arthritis Drug Market with many aspects of the industry like the market size, market status, market trends and forecast, the report also provides brief information of the competitors and the specific growth opportunities with key market drivers. Find the complete Polyarticular Juvenile Idiopathic Arthritis Drug Market analysis segmented []

Jumbo News | June 10, 2021

Company News for Jun 7, 2021

Companies in the news are: REGN, CHRS, SENS, CGEM

Yahoo | June 7, 2021

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

InvestorPlace is kicking off Friday with a look at the biggest pre-market stock movers for the day as we prepare for that weekend break.

William White on InvestorPlace | June 4, 2021

Coherus, Junshi Toripalimab-Chemo Combo Beat Chemo Alone in Late-Stage Nose & Throat Cancer Trial

Shanghai Junshi Biosciences Co Ltd and Coherus BioSciences Inc (NASDAQ: CHRS ) have announced positive results from the pivotal Phase 3 JUPITER-02 trial evaluating toripalimab plus chemotherapy for the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma (NPC). The results will be presented at the annual meeting of the American Society for Clinical Oncology. The interim analysis met the primary endpoint, demonstrating a statistically significant and Full story available on

Benzinga | June 4, 2021

Read More 'CHRS' Stories Here

CHRS Price Returns

1-mo 14.25%
3-mo 1.48%
6-mo N/A
1-year -15.00%
3-year -12.38%
5-year -1.63%
YTD -13.29%
2020 -3.47%
2019 98.95%
2018 2.84%
2017 -68.74%
2016 22.60%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 1.7593 seconds.